In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography

Clinical Pharmacology and Therapeutics
Jussi Hirvonen

Abstract

Positron emission tomography (PET) can visualize and quantify receptors and other targets in the living human brain, and recent progress in radioligand development has enabled measurement of cannabinoid type-1 (CB1 ) receptors. Cannabinoid CB1 receptors have been implicated in multiple human diseases, such as obesity, mood disorders, and addiction. First in vivo human studies have shown distinctive spatial and temporal alterations in cannabinoid CB1 receptor binding in addictive disorders.

References

Apr 27, 2002·Science·Rachel I Wilson, Roger A Nicoll
Jul 5, 2005·Trends in Pharmacological Sciences·Taco J De Vries, Anton N M Schoffelmeer
Dec 17, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Garth E TerryRobert B Innis

❮ Previous
Next ❯

Citations

Mar 25, 2015·Clinical Pharmacology and Therapeutics·B Le Foll, R F Tyndale
Oct 5, 2016·Forensic Science International : Synergy·Percy BondallazChristian Giroud
Sep 1, 2018·Acta Pharmacologica Sinica·Matthew E SloanBernard Le Foll
Jun 1, 2020·Physiology & Behavior·Dianne P Figlewicz, Renger F Witkamp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.